STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 135515

TO: Alton Pryor **Location: REM 4A39** **Art Unit: 1616** **October 19, 2004** **Case Serial Number: 10/049821**	**From: P. Sheppard** **Location: Remsen Building** **Phone: (571) 272-2529** **sheppard@uspto.gov**

Held

Search Notes

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 15:28:08 ON 19 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 19 Oct 2004  VOL 141 ISS 17
FILE LAST UPDATED: 18 Oct 2004  (20041018/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=>
=>

=> d stat que
L3                STR
```




```
VAR G1=C/N
VAR G2=C/N/O/S
REP G3=(1-4) C
REP G5=(2-4) A
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  15

STEREO ATTRIBUTES: NONE
L9            92 SEA FILE=REGISTRY SSS FUL L3
L10            2 SEA FILE=REGISTRY ABB=ON  PLU=ON  ("LAURIC DIETHANOLAMIDE"/CN
                 OR "LAURIC DIETHANOLAMINE"/CN)
L11           37 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L9
L12               SEL  PLU=ON  L10 1- CHEM :     101 TERMS
L13         7054 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L12
L14         7142 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L13 OR LAUR?(A)DIETHANOL?
```

L15 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L11 AND L14

=>
=>

=> d ibib abs hitstr l15 1

L15 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:152517 HCAPLUS
DOCUMENT NUMBER: 134:183534
TITLE: Percutaneous absorption agents containing melatonin agonists
INVENTOR(S): Suzuki, Yasuyuki; Iga, Katsumi; Miyamoto, Masaomi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001013950	A1	20010301	WO 2000-JP5525	20000818
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2001131089	A2	20010515	JP 2000-254233	20000818
EP 1214944	A1	20020619	EP 2000-953481	20000818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.: JP 1999-234106 A 19990820
WO 2000-JP5525 W 20000818

OTHER SOURCE(S): MARPAT 134:183534

AB Percutaneous absorption agents which make it possible to absorb compds. having a melatonin receptor agonism via a convenient administration system, have favorable blood concentration passage characteristics and can exert a therapeutic effect on a disease caused by a decrease in melatonin at night. The compns. comprise melatonin agonists and ≥ 1 compds. selected from the group consisting of fatty acid esters, polyhydric alcs., and nonionic surfactants. A patch was prepared containing (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide 7.5, DuroTak 87-2979 47.5, **lauric acid diethanolamide** 5.0, iso-Pr myristate 20, and propylene glycol 20 %.

IT **326793-94-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(transdermal prepns. containing melatonin agonists for treatment of sleep disorders)

RN 326793-94-6 HCAPLUS
CN Acetamide, N-[2-[(8S)-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **196597-26-9**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transdermal prepns. containing melatonin agonists for treatment of sleep disorders)
RN 196597-26-9 HCAPLUS
CN Propanamide, N-[2-[(8S)-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **120-40-1, Lauric acid diethanolamide**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transdermal prepns. containing melatonin agonists for treatment of sleep disorders)
RN 120-40-1 HCAPLUS
CN Dodecanamide, N,N-bis(2-hydroxyethyl)- (6CI, 8CI, 9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> □

=> d stat que nos l22
L3 STR
L9 92 SEA FILE=REGISTRY SSS FUL L3
L10 2 SEA FILE=REGISTRY ABB=ON PLU=ON ("LAURIC DIETHANOLAMIDE"/CN OR "LAURIC DIETHANOLAMINE"/CN)
L11 37 SEA FILE=HCAPLUS ABB=ON PLU=ON L9
L12 SEL PLU=ON L10 1- CHEM : 101 TERMS
L13 7054 SEA FILE=HCAPLUS ABB=ON PLU=ON L12

```
L14         7142 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L13 OR LAUR?(A)DIETHANOL?
L15            1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L11 AND L14
L16          158 SEA FILE=REGISTRY ABB=ON  PLU=ON  (MELATONIN/BI OR MELATONINE/B
                 I)
L17        13472 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L16 OR ?MELATONIN?
L21            3 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L14 AND L17
L22            2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L21 NOT L15


=>
=>

=> d ibib abs hitstr l22 1-2

L22  ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         2000:14983  HCAPLUS
DOCUMENT NUMBER:          132:83650
TITLE:                    Solid dispersed preparation of poorly water-soluble
                          drug containing oil, fatty acid or mixtures thereof
INVENTOR(S):              Lee, Beom Jin
PATENT ASSIGNEE(S):       Won Jin Biopharma Co., Ltd., S. Korea
SOURCE:                   PCT Int. Appl., 67 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2000000179         A1    20000106    WO 1999-KR341            19990628
         W:  AU, CA, CN, JP, US
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE
     KR 2000006503         A     20000125    KR 1999-24437            19990626
     AU 9946556            A1    20000117    AU 1999-46556            19990628
PRIORITY APPLN. INFO.:                       KR 1998-24563       A    19980627
                                             KR 1999-24437       A    19990626
                                             WO 1999-KR341       W    19990628

AB   Disclosed is a solid dispersed preparation for poorly water-soluble drugs, which
     is prepared by dissolving or dispersing the poorly water-soluble drugs in an
     oil, a fatty acid or a mixture thereof, mixing the solution or dispersion in a
     water-soluble polyol matrix and drying the mixture  The solid dispersed preparation
     can be formulated into a power formulation or a granule formulation.  The
     solid dispersed preparation is improved in the solubility of poorly water-soluble
drugs
     in the gastro-intestinal tract, resulting in a great increase in the
     bioavailability of the drugs.  In addition, the solid dispersed preparation gives
     the pharmaceutical solns. to the problems that the conventional semi-solid
     or liquid prepns. possess, enabling medicinally effective, poorly water-soluble
     compds. to be formulated, molded and processed, quickly and in an
     economically favorable manner without use of any organic solvent.  Examples
     are given for emulsions containing mixts. of waxes, oils, and aqueous phase.
IT   73-31-4, Melatonin 120-40-1D, Lauric
     acid diethanolamide, coco acyl derivs.
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (solid dispersed preparation of poorly water-soluble drug containing oils and
fatty
        acid or mixts.)
RN   73-31-4  HCAPLUS
CN   Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]- (9CI)  (CA INDEX NAME)
```



RN 120-40-1 HCAPLUS
CN Dodecanamide, N,N-bis(2-hydroxyethyl)- (6CI, 8CI, 9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1998:268388 HCAPLUS
DOCUMENT NUMBER: 128:326524
TITLE: Permeation enhancers for transdermal drug delivery compositions, devices,and methods
INVENTOR(S): Lee, Eun Soo; Yum, Su Il
PATENT ASSIGNEE(S): Alza Corp., USA
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9817315	A2	19980430	WO 1997-US18956	19971023
WO 9817315	A3	19980702		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2264687	AA	19980430	CA 1997-2264687	19971023
AU 9749907	A1	19980515	AU 1997-49907	19971023
EP 934078	A2	19990811	EP 1997-912815	19971023
EP 934078	B1	20021218		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001502693	T2	20010227	JP 1998-519563	19971023
AT 229817	E	20030115	AT 1997-912815	19971023
ES 2191834	T3	20030916	ES 1997-912815	19971023

PRIORITY APPLN. INFO.: US 1996-30424P P 19961024
WO 1997-US18956 W 19971023

AB The present invention is directed to the transdermal administration of at least one drug together with a suitable amount of a permeation enhancer comprising monoalkyl ethers of polyethyleneglycol and their alkyl or aryl carboxylic acid esters and carboxymethyl ethers. The invention includes a

transdermal drug delivery device comprising a matrix adapted to be placed in drug-and-permeation enhancer-transmitting relation with a skin site. The matrix contains sufficient amts. of the permeation enhancer and drug, in combination, to continuously administer drug to the systemic circulation of a patient at a therapeutically effective rate. The invention is also directed to compns. and methods for transdermal administration of at least one drug together with a permeation enhancer of this invention, alone or in combination with other enhancers. Laureth-4 (30 weight%) alone exhibited about a 4-fold increase in testosterone permeation compared to a sample without any permeation enhancer.

IT **73-31-4, Melatonin 120-40-1,** Dodecanamide, N,N-bis(2-hydroxyethyl)-
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(permeation enhancers for transdermal drug delivery compns.)

RN 73-31-4 HCAPLUS
CN Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 120-40-1 HCAPLUS
CN Dodecanamide, N,N-bis(2-hydroxyethyl)- (6CI, 8CI, 9CI) (CA INDEX NAME)



=> □

=> d stat que nos
L3 STR
L9 92 SEA FILE=REGISTRY SSS FUL L3
L11 37 SEA FILE=HCAPLUS ABB=ON PLU=ON L9
L31 11 SEA FILE=HCAPLUS ABB=ON PLU=ON L11 (L)(?MEDICI? OR ?THERAP? OR ?DRUG? OR ?PHARM?)
L33 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L31 AND SLEEP

=> d ibib abs hitstr l33 1

L33 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1999:795635 HCAPLUS
DOCUMENT NUMBER: 132:40535
TITLE: Pharmaceutical composition for treating or preventing **sleep** disorders
INVENTOR(S): Ohkawa, Shigenori; Miyamoto, Masaomi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9963977	A2	19991216	WO 1999-JP3057	19990608
WO 9963977	A3	20010329		
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2332521	AA	19991216	CA 1999-2332521	19990608
AU 9940605	A1	19991230	AU 1999-40605	19990608
JP 2000063272	A2	20000229	JP 1999-160568	19990608
JP 3509637	B2	20040322		
EP 1100508	A2	20010523	EP 1999-923960	19990608
EP 1100508	B1	20030827		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 247967	E	20030915	AT 1999-923960	19990608
US 6348485	B1	20020219	US 2000-700405	20001114
PRIORITY APPLN. INFO.:			JP 1998-160270 A	19980609
			WO 1999-JP3057 W	19990608

AB The present invention provides a pharmaceutical composition for treating or preventing **sleep** disorders which comprises (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide (I) in combination with at least 1 active component selected from zolpidem, zopiclone, triazolam and brotizolam. Thus, I was obtained in a series of steps starting from 2,3-dihydrobenzofuran-5-carbaldehyde. Tablets were prepared from I 10.0, lactose 60.0, corn starch 35.0, gelatin 3.0, and Mg stearate 2.0 g. Treatment with compound I (0.003 mg/kg, p.o.) had no significant effects on the latency of any **sleep** stages. Treatment with triazolam alone (0.03 mg/kg) did not affect general behavior and it did not cause ataxia and sedation as such were seen when high doses of triazolam are given. Co-administration of I and triazolam shortened the latencies of deep slow wave **sleep**, stage 3 and stage 4, and it significantly shortened the latency of the stage 4 **sleep**. The co-administration also had no significant effects on general behavior of monkeys.

IT **196597-26-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**pharmaceutical** composition for treating or preventing **sleep** disorders)

RN 196597-26-9 HCAPLUS
CN Propanamide, N-[2-[(8S)-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


O
Et
N
H
S
O

=>